YMAB
Y-mAbs Therapeutics
YMAB
YMAB
Delisted
YMAB was delisted on the 15th of September, 2025.
105 hedge funds and large institutions have $339M invested in Y-mAbs Therapeutics in 2024 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 38 increasing their positions, 28 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
11% more funds holding
Funds holding: 95 → 105 (+10)
2.26% more ownership
Funds ownership: 55.49% → 57.75% (+2.3%)
Holders
105
Holding in Top 10
1
Calls
$563K
Puts
$5K
Top Buyers
| 1 | +$10.5M | |
| 2 | +$8.06M | |
| 3 | +$5.33M | |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
+$2.84M |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$2.47M |
Top Sellers
| 1 | -$3.66M | |
| 2 | -$3.47M | |
| 3 | -$3.26M | |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$2.85M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.83M |